Similarly, the CAR-T drug C-CAR031 (CTR20243113, NCT05155189), targeting GPC3, has demonstrated good safety and significant antitumor activity in liver cancer patients, with 14/24 patients achieved objective response and 91.3% disease controlled [50]. This evidence concerns the gene GPC3 and liver cancer.